The delicate skin around the eyes is often the first to show signs of aging, but it is also the most difficult area to treat with traditional fillers. In 2026, the "Under-Eye" segment has become the most profitable niche for polynucleotide manufacturers. Because PNs are non-hydrophilic (they don't attract excessive water), they carry a much lower risk of puffiness or "Tyndall effect" compared to HA fillers in the tear trough area.

Data from the Polynucleotides Injectable Market segment analysis indicates that "Eye Rejuvenation" accounts for over 60% of polynucleotide revenue in several major clinics. Patients are seeing remarkable improvements in dark circles, which are often caused by thinning skin and poor circulation rather than just pigment. By thickening the dermal layer, PNs effectively "hide" the underlying blood vessels, leading to a brighter, fresher look.

This segment’s growth is also being fueled by the "Screen-Fatigue" phenomenon. In our digitally-dominated world, people are more aware of their under-eye area than ever before. Clinics are now offering specialized "Digital Detox" packages that combine PN injections with blue-light protection skincare. As the technology continues to specialize, we expect to see "periorbital-specific" polynucleotide formulations that are optimized for the thinnest skin on the human body.

❓ Frequently Asked Questions

Q: Can polynucleotides help with dark circles? A: Yes, by thickening the skin and improving microcirculation, they can significantly reduce the appearance of dark circles caused by thin skin.

Q: Is there a risk of lumps under the eyes? A: Because polynucleotides integrate into the tissue rather than sitting on top of it like a filler, the risk of visible lumps is extremely low.

Browse More Reports:

Micro Robots Market

Cheminformatics Market

Rapid Diagnostics Market

Fracture Fixation Products Market

Respiratory Drugs Market

Extremity Products Market